References

1. Stief CG, Ziegler D. Diabetic autonomic neuropathy. Urogenital system, In Textbook of diabetic neuropathy (Gries FA, Cameron NE, Low PA, Ziegler D, eds.), Thieme, Stuttgart, New York, 2003;262-274.

2. Paro M, Prashar A, Prosdocimi M, Cherian PV, Fiori MG, Sima, AAF. Urinary bladder dyfunction in the BB/W diabetic rat. J Urol 1994;151:781-786.

3. Liu G, Daneshgari F. Alterations in neurogenically mediated contractile responses of urinary bladder in rats with diabetes. Am J Physiol Renal Physiol 2005;288:F1220-F1226.

4. Mannikarottu AS, Changolkar AK, Disanto ME, Wein AJ, Chacko S. Over expression of smooth muscle thin filament associated proteins in the bladder wall of diabetics. J Urol 2005;174:360-364.

5. Ellenberg M. Development of urinary bladder dysfunction in diabetes mellitus. Ann Int Med 1980;92:321-323.

6. Kaplan SA, Blavas TeAE, Urodynamic findings in patients with diabetic cystopathy. J Urol 1995;153:342-344.

7. Starer P, Libow L. Cystometric evaluation of bladder dysfunction in elderly diabetic patients. Arch Intern Med 1990;150:810-816.

8. Brown JS, Wessells H, Chancellor MB, et al. Urologic complications of diabetes. Diabetes Care 2005;28:177-185.

9. Jackson RA, Vittinghoff E, Kanaya AM, et al. Aging and Body Composition (Health ABC) Research Group: Urinary incontinence in elderly women: finding from the Health, Aging, and Body Composition Study. Obstet Gynecol 2004;104:301-307.

10. Thon WF, und Stief CG. Blasenfunktionsstörungen als urologische DiabetesKomplikation. Der Kassenarzt 1996;23:40-48.

11. Thon WF, und Grünewald V. Neurostimulation. Curr Opin Urol 1993;3:295-302.

12. Grünewald V, Thon WF, Jonas U. Neuromodulation bei neurogener Blasenfunktionsstörung, In Neurogene Blasenfunktionsstörungen (herausgeg von Stöhrer M, Madersbacher H, und Palmtag H, eds.), Springer, Heidelberg 1996, pp. 163-175.

13. Thon WF. Elektrostimulation der sakralen Spinalnerven bei Blasenfunktionsstörungen. Med Welt 1994;45:195-203.

14. Eri LM, Tveter KJ. Alpha blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995;154:923-934.

15. Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23.

16. Wagner G, Saenz de, Tejada I. Update on male erectile dysfunction. Br Med J 1998;316: 678-682.

17. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male ageing study. J Urol 1994;151:54-61.

18. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the "Cologne Male Survey." Int J Impot Res 2000;12:305-311.

19. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000;163:460-463.

20. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996;19:135-141.

21. Fedele D, Coscelli C, Santeusanio F, et al. Erectile dysfunction in diabetic subjects in Italy. Diabetes Care 1998;21:1973-1977.

22. Parazzini F, Menchini FF, Bortolotti A, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol 2000;37:43-49.

23. Lustman PJ, Clouse RE. Relationship of psychiatric illness to impotence in men with diabetes. Diabetes Care 1990;13:893-895.

24. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-1813.

25. Saenz de Tejada I, Goldstein I. Diabetic penile neuropathy. Urol Clin North Am 1988;15:17-22.

26. Seftel AD, Vaziri ND, Ni Z, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997;50:1016-1026.

27. Hirata K, Kuroda R, Sakoda T, et al. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 1995;25:180-185.

28. Saenz de, Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-1030.

29. Keegan A, Cotter MA, Cameron NE. Effects of diabetes and treatment with the antioxidant a-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia 1999;42:343-350.

30. Elabbady AA, Gagnon C, Hassouna MM, Begin LR, Elhilali MM. Diabets mellitus increases nitric oxide synthase in penises but not in major pelvic ganglia of rats. Br J Urol 1995;76:196-202.

31. Vernet D, Cai L, Garban H, et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction.

Endocrinology 1995;136:5709-5717.

32. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004;101:9121-9126.

33. American Urological Association. Management of Erectile Dysfunction ('05/updated'06), http://www.auanet.org/guidelines/main_reports/edmgmt/chapter1.pdf.

34. Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. BMJ 2000;321:499-503.

35. Azad N, Emanuele NV, Abraira C, et al. The effects of intensive glycemic control on neuropathy in the VA Cooperative Study on Type II diabetes mellitus. J Diabetes Complications 2000;13:307-313.

36. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978-2984.

37. Vogt HJ, Brandl P, Kockott G, et al. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int JImpotRes 1997;9(3):155-161.

38. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and metaanalysis of randomized clinical trials. J Urol 1998;159:433-436.

39. Rampin O, Bernabe J, Guilano F. Spinal control of penile erection. World J Urol 1997;15:2-13.

40. Padma-Nathan H, Auerbach S, Lewis R, Lewand M, et al. Efficacy and safety of Apomorphin vs placebo for male erectile dysfunction. J Urol 1999;161:821.

41. Lewis R, Agre K, Rudd D. Efficacy of Apomorphin vs Placebo for erectile dysfunction in patients with hypertension. J Urol 1999;161:822.

42. Reproductive Health Drugs Advisory Committee. Urology Subcommittee. www.fda.gov/ ohrms/dockets/ac/00/transcripts/36021.rtf.

43. Küthe A, Wiedentoth A, Stief C, Mägert H, Forssmann W, Jonas U. Identification of 13 PDE isoforms in human cavernous tissue. Eur Urol 1999;35:404.

44. Taher A, Stief CG, Raida M, Jonas U, Forssmann WG. Cyclic nucleotide phosphodi-esterase activity in human cavernous smooth muscle and the effect of various selective inhibitors. Int J Impotence Res 1992;4(Suppl 2):P11.

45. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-426.

46. Boulton AJM, Selam J-L, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001;44:1296-1301.

47. Sellam R, Ziegler D, Boulton AJM. Sildenafil citrate is effective and well tolerated for the treatment of erectile dysfunction in men with Type 1 or Type 2 diabetes mellitus. Diabetologia 2000;43(Suppl 1):A253.

48. Mitka M. Some men who take Viagra die—Why? JAMA 2000;283:590-593.

49. Shakir SAW, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. Br Med J 2001;322:651-652.

50. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-1626.

51. De Angelis L, Marfella MA, Siniscalchi M, et al. Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia 2001;44:1155-1160.

52. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002;25:1336-1339.

53. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodi-esterase inhibition with Sildenafil enhances Flow mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-851.

54. Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999;99:168-177.

55. Stolk EA, Busschbach JJ, Caffa M, Meuleman EJ, Rutten FF. Cost utility analysis of sildenafil compared with papaverine-phentolamine injections. BMJ 2000;320:1165-1168.

56. Smith KJ, Roberts MS. The cost-effectiveness of sildenafil. Ann Intern Med 2000;132: 933-937.

57. Wespes E, Rammal A, Garbar C. Sildenafil non-responders: haemodynamic and morpho-metric studies. Eur Urol 2005;48:136-139.

58. Saenz de, Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-2164.

59. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-1923.

60a. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-783.

60b. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006;3:883-891.

61. Becker AJ, Stief CG, Machtens S, Schultheiss D, Truss MC, Jonas U. Oral phentolamine as treatment for erectile dysfunction. J Urol 1998;159:1214-1216.

62. Dutta TC, Eid JF. Vacuum constriction devices for erectile dysfunction: a long-term, prospective study of patients with mild, moderate, and severe dysfunction. Urology 1999; 54:891-893.

63. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1-7.

64. Porst H. Transurethrale Alprostadilapplikation mit MUSE™ (medicated urethral system for erection). Urologe [A] 1998;37:410-416.

65. Spivack AP, Peterson CA, Cowley C, et al. Long-term safety profile of transurethral alprostadil for the treatment of erectile dysfunction. J Urol 1997;157(Supp l):203.

66. Fulgham PF, Cochran JS, Denman JL, et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998;160:2041-2046.

67. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334:873-877.

68. Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology 2000;55:109-113.

69. Porst H, Buvat J, Meuleman EJH, Michal V, Wagner G. Final results of a prospective multicenter study with self-injection therapy with PGE1 after 4 years of follow-up. Int J Impot Res 1996;6:151:D118.

70. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986;9:648-665.

71. Enzlin P, Mathieu C, Van Den Bruel A, Vanderschueren D, Demyttenaere K. Prevalence and predictors of sexual dysfunction in patients with type 1 diabetes. Diabetes Care 2003;26:409-414.

72. Esposito K, Ciotola M, Marfella R, Di Tommaso D, Cobellis L, Giugliano D. The metabolic syndrome: a cause of sexual dysfunction in women. Int J Impot Res 2005;17:224-226.

73. Enzlin P, Mathieu C, Vanderschueren D, Demyttenaere K. Diabetes mellitus and female sexuality: a review of 25 years' research. Diabetes Med 1998;15:809-815.

74. Jovanovic L. Sex and the woman with diabetes: desire versus dysfunction. IDF Bull 1998;43:23-28.

Dealing With Erectile Dysfunction

Dealing With Erectile Dysfunction

Whether you call it erectile dysfunction, ED, impotence, or any number of slang terms, erection problems are something many men have to face during the course of their lifetimes.

Get My Free Ebook


Post a comment